Here are the answers to your questions based on the provided information:
1. Which of the following treatments can be considered precision medicine?
✅ C. CAR-T cell therapy targeting gp-120 against HIV-infected cells
(Precision medicine involves targeted therapies based on specific molecular or genetic characteristics, such as engineered T-cells for HIV.)
❌ Other options:
- A (chemo/radiotherapy for NSCLC) → Not inherently precise.
- B (antibiotics for infection) → Standard treatment, not personalized.
- D (Treg induction for T1D) → Experimental but not yet established precision medicine.
- E (chemotherapy nanoparticles) → Drug delivery improvement, not necessarily precision-based.
2. In the study by Xu et al (2012), what is the role of photodynamic therapy (PDT) in cancer vaccines?
✅ B. Promote recruitment and maturation of DCs at the tumour site
(PDT induces immunogenic cell death, attracting dendritic cells to enhance anti-tumor immune responses.)
❌ Other options:
- A (direct CTL activation) → PDT does not directly activate CTLs.
- C (particle uptake by DCs) → Related to nanoparticle delivery, not PDT’s primary role.
- D (targeting MSNs) → Nanoparticle delivery mechanism, not PDT’s function.
- E (imaging guidance) → Secondary benefit, not main immunological role.
3. According to Raez et al (2023), which parameter most influenced doctors’ choice between liquid vs tissue biopsy?
✅ E. Turnaround time (The study found that faster results from liquid biopsies often drove clinical decisions.)
❌ Other options: While biomarker detection and survival matter, turnaround time was most critical in practice.
4. Which trial collects data to test clinical utility?
✅ A. SHIVA02 (Tests whether molecularly targeted therapies improve outcomes compared to standard care.)
❌ Other trials focus on specific drugs or combinations rather than broad utility validation:
- B/C/D/E investigate particular treatments, not general clinical utility frameworks.
5. Which two trials studied similar sets of target molecules?
✅ B. CONCORD and SHIVA02 (Both assess pan-cancer molecular profiling to guide therapy selection.)
❌ Other pairings mismatch trial designs: e.g., I-PICC/SHIVA differ in scope; BEACON CRC focuses on colorectal cancer only.
Let me know if you need further clarification!
内容由零声教学AI助手提供，问题来源于学员提问
